Home > Insider Trading > Filing (0001638599-18-000707)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1682639	Eyenovia Inc.	EYEN	Pharmaceutical Preparations (2834)	471178401

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1728916	Tsontcho Ianchulev	C/O Eyenovia Inc. 501 Fifth Avenue, Suite 1404 New York NY 10017	Chief Executive Officer	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $.0001	Acquisiton	2018-06-28	6,000	$6.63	6,000	No	4	P	Indirect	By The Meliora Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By The Meliora Trust

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, Par Value $.0001	18,749	Direct
Common Stock, Par Value $.0001	466,667	Indirect	By Private Medical Equity, Inc.
Common Stock, Par Value $.0001	453,333	Indirect	By PME Investor Services Eyenovia, LLC

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (right to buy)	$1.24	2015-03-02	2025-03-02	40,000	40,000	Direct
Common Stock	Stock Option (right to buy)	$1.95		2027-07-07	401,056	401,056	Direct
Common Stock	Stock Option (right to buy)	$1.24	2015-03-23	2025-03-23	280,000	280,000	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2025-03-02	40,000	40,000	Direct
2027-07-07	401,056	401,056	Direct
2025-03-23	280,000	280,000	Indirect

Footnotes

This transaction was executed in multiple trades ranging from $6.35 to $6.73. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder full information regarding the number of shares and prices at which the transactions were effected.
The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The option became exercisable as to 11,140 shares on August 7, 2017, and becomes exercisable in equal 11,140 share amounts on each of the 35 one-month anniversaries thereafter.